Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study
Part of paid clinical trials in Chapel Hill, North Carolina.
- Sponsor
- University of North Carolina, Chapel Hill
- Study ID
- NCT06158113
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Lichen Planus, Mucosal
- Lichen Planus, Oral
- Oral Lichen Planus
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Baricitinib 4 milligram Oral Tablet — DRUG4 milligrams once daily
Study Details
The goal of this clinical trial is to learn the effects of baricitinib (the study drug) in patients with Oral Lichen Planus. The main questions it aims to answer are: * What is the efficacy of baricitinib in treating moderate to severe Oral Lichen Planus? * Can baricitinib treatment in Oral Lichen Planus change quality of life? * What side effects do patients with Oral Lichen Planus experience when treated with baricitinib? Participants will be required to come in to monthly visits for up to eight months. During visits, participants will be: * Evaluated for the extent of their disease * Asked to fill out a questionnaire about their quality of life * Given baricitinib for them to take at home for six months * Evaluated for any potential side experienced while on treatment * Asked to return 1 month after completing treatment
Key Dates
- Start date
- Mar 13, 2024
- Status verified
- Mar 2026
- Primary completion
- Aug 31, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: BaricitinibParticipants will be asked to take 4mg of baricitinib by mouth daily for up to 24 weeks.
Primary Outcome Measure
Change in Oral Disease Severity Scale (ODSS) Scores [ Time Frame: Baseline, 24 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UNC Dermatology and Skin Cancer Center | Chapel Hill | North Carolina | 27516 | - |